Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia

Published:2021-03-19 Issue:12 Volume:127 Page:2025-2038
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Jabbour Elias¹^ORCID,Sasaki Koji¹^ORCID,Short Nicholas J.¹^ORCID,Ravandi Farhad¹,Huang Xuelin²,Khoury Joseph D.³,Kanagal‐Shamanna Rashmi³^ORCID,Jorgensen Jeffrey³,Khouri Issa F.⁴^ORCID,Kebriaei Partow⁴,Jain Nitin¹,Alvarado Yesid¹,Kadia Tapan M.¹^ORCID,Paul Shilpa⁵,Garcia‐Manero Guillermo¹^ORCID,Dabaja Bouthaina S.⁶^ORCID,Burger Jan A.¹,DiNardo Courtney D.¹^ORCID,Daver Naval A.¹^ORCID,Montalban‐Bravo Guillermo¹^ORCID,Yilmaz Musa¹,Ohanian Maro¹,Ferrajoli Alessandra¹,Jacob Jovitta¹,Rostykus Meagan¹,Garris Rebecca¹,O’Brien Susan⁷,Kantarjian Hagop M.¹^ORCID

Affiliation:

1. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas

2. Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas

3. Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas

4. Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas

5. Department of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas

6. Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas

7. Chao Family Comprehensive Cancer Center University of California Irvine Orange California

Funder

Pfizer

Amgen

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33469

Reference37 articles.

1. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia

2. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

3. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

4. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

5. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies;Molecular Therapy;2024-08

3. Dermatologic toxicities of antibody-drug conjugates;Journal of the American Academy of Dermatology;2024-08

4. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions;Journal of Hematology & Oncology;2024-05-11

5. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia;Blood Advances;2024-03-13